AbbVie cuts Q3 EPS forecast to $3.73-$3.77 on $216 mln expense

AbbVie cut its Q3 adjusted diluted EPS guidance to USD 3.73-3.77 from USD 3.84-3.88, citing acquired IPR&D and milestones expense of USD 216 million, equal to a USD 0.11 per-share hit. Full-year guidance was also lowered.